680 related articles for article (PubMed ID: 16698685)
1. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
2. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
3. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
4. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
5. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
[TBL] [Abstract][Full Text] [Related]
6. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
[TBL] [Abstract][Full Text] [Related]
7. Human gammadelta T cells modulate the mite allergen-specific T-helper type 2-skewed immunity.
Korematsu S; Tanaka Y; Nagakura T; Minato N; Izumi T
Clin Exp Allergy; 2007 Nov; 37(11):1681-7. PubMed ID: 17883427
[TBL] [Abstract][Full Text] [Related]
8. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
10. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of type I IFNs on the growth of WC1- CD8+ gamma delta T cells and WC1+ CD8- gamma delta T cells in vitro.
Tuo W; Bazer FW; Davis WC; Zhu D; Brown WC
J Immunol; 1999 Jan; 162(1):245-53. PubMed ID: 9886392
[TBL] [Abstract][Full Text] [Related]
12. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
13. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
[TBL] [Abstract][Full Text] [Related]
14. Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons.
Kunzmann V; Kretzschmar E; Herrmann T; Wilhelm M
Immunology; 2004 Jul; 112(3):369-77. PubMed ID: 15196204
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
16. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.
Haas JD; González FH; Schmitz S; Chennupati V; Föhse L; Kremmer E; Förster R; Prinz I
Eur J Immunol; 2009 Dec; 39(12):3488-97. PubMed ID: 19830744
[TBL] [Abstract][Full Text] [Related]
17. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
[TBL] [Abstract][Full Text] [Related]
18. Comparison of phenotype of gammadelta T cells generated using various cultivation methods.
Mehrle S; Watzl C; von Lilienfeld-Toal M; Amoroso A; Schmidt J; Märten A
Immunol Lett; 2009 Jun; 125(1):53-8. PubMed ID: 19505505
[TBL] [Abstract][Full Text] [Related]
19. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
Guo BL; Liu Z; Aldrich WA; Lopez RD
Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
[TBL] [Abstract][Full Text] [Related]
20. Modulation of innate immunity by IL-18.
Li W; Yamamoto H; Kubo S; Okamura H
J Reprod Immunol; 2009 Dec; 83(1-2):101-5. PubMed ID: 19853308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
